Dachaigh › Cancer briste triple-negative › Oregon › Portland
Sgrùdaidhean clionaigeach Cancer briste triple-negative ann an Portland, OR
Tha 9 sgrùdaidhean airson Cancer briste triple-negative a’ lorg phàirtichean aig làraichean ann agus timcheall air Portland (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- Oregon Health & Science University (OHSU), Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Avenzo Therapeutics Recruiting Site, Portland
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A’ fastadhÌre 3
- Providence Portland Medical Center ( Site 0116), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0126), Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
A’ fastadhÌre 2
- Providence Portland Cancer Institute - Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A’ fastadhÌre 3
- Oregon Health & Science University, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- Compass Oncology - Rose Quarter, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A’ fastadhÌre 2
- Oregon Health & Science Institute (OHSU), Portland
Sgrùdaidhean Cancer briste triple-negative ann am bailtean eile
- Houston, TX42 sgrùdaidhean
- New York City, NY31 sgrùdaidhean
- Nashville, TN28 sgrùdaidhean
- Los Angeles, CA27 sgrùdaidhean
- Boston, MA26 sgrùdaidhean
- San Antonio, TX23 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
- Arlington, VA20 sgrùdaidhean
- Atlanta, GA20 sgrùdaidhean
- Dallas, TX18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Columbus, OH16 sgrùdaidhean
Sgrùdaidhean eile ann an Portland
- Aillse Sgamhain Neo-chealla-beag46 sgrùdaidhean
- Aillse (gach seòrsa)34 sgrùdaidhean
- Aillse a' bhroilleach33 sgrùdaidhean
- Aillse Prostata33 sgrùdaidhean
- Ailse metastatach29 sgrùdaidhean
- Aillse colorectal28 sgrùdaidhean
- Cancer Ovarian27 sgrùdaidhean
- Ailseachadh nan Sgamhan26 sgrùdaidhean
- Leukemia myeloid geur25 sgrùdaidhean
- Ailse Endometrial24 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil19 sgrùdaidhean
- Cancer Pancreatic19 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.